Qian-Li Ma

Publications (3)3.36 Total impact

• Article: [The significance of cough reflex sensitivity test in chronic cough].

  Qian-li Ma, Zhou Long, Qiao Zhang, Zan-sheng Huang, Ying Wu, Chang-zheng Wang
  [show abstract] [hide abstract]
  ABSTRACT: Preliminary study of the cough reflex sensitivity test in chronic cough patients with different gender, disease duration and causes to evaluate the clinical diagnostic significance of the test and further provide some information for the treatment of chronic cough. Totally 108 chronic cough patients in our hospital were enrolled in the study with the final diagnosis of upper airway cough syndrome (UACS), cough variant asthma (CVA) and gastroesophageal reflux cough (GERC). They all went through the cough reflex sensitivity test and the retrospective analysis of the results was made. In 108 patients with chronic cough (76 UACS, 19 CVA and 13 GERC), lgC5 was significantly slower in the female (1.80) than the male (2.40, P < 0.05) and in the patients with cough duration over 12 months (1.80) than those with cough duration under 12 months (2.40, P < 0.05). Cough sensitivity in patients with different causes was significantly different (P < 0.05) with lower lgC5 in GERC patients (1.49) than CVA (2.40, P < 0.05) and UACS (2.40, P < 0.05) patients. Cough sensitivity is different in chronic cough patients with different gender, disease duration and causes. Cough reflex sensitivity test is of great value in the etiology diagnosis of chronic cough.
  Zhonghua nei ke za zhi [Chinese journal of internal medicine] 08/2011; 50(8):668-71.
• Source

  Available from: PubMed Central

  Article: Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in COPD.

  Li Yang, Qian-li Ma, Wei Yao, Qiao Zhang, Hua-ping Chen, Guan-song Wang, Chang-zheng Wang
  [show abstract] [hide abstract]
  ABSTRACT: Salmeterol and fluticasone combination (SFC) has anti-inflammatory effects and improves clinical symptoms in patients with chronic obstructive pulmonary disease (COPD). However, the anti-inflammatory mechanism of SFC remains unclear. In this study, we investigated the inflammatory responses of COPD, as well as the relationship of the inflammatory factors with the levels of CD4+CD25+Foxp3+ regulatory T cells (Foxp3+Tregs) after SFC therapy. Twenty-one patients with moderate or severe COPD received treatment with 50/500 μg of SFC twice a day for 12 weeks. Before and after treatment, the patients were evaluated using the Modified Medical Research Council (MMRC) dyspnea scale and by conducting a 6-min walk test. The number of neutrophils, monocytes and lymphocytes in induced sputum were counted. Levels of cytokines, including pre-inflammatory IL-8, TNF-α, IL-17A and cytokine IL-10, in the sputum supernatant and peripheral blood were measured by ELISA. The proportion of Foxp3+Tregs in the total CD4+ T cell of the peripheral blood was determined by flow cytometry. The relationship between IL-17A levels and the percentage of Foxp3+Tregs was analyzed by statistical analysis. After treatment with SFC, the forced expiratory volume in 1 s as a percentage of predicted values (FEV1%) and the 6-min walk distance in the COPD patients significantly increased, while dyspnea scores decreased. The total number of cells, neutrophils, and the percentage of neutrophils in induced sputum reduced notably, while the proportion of monocytes was significantly increased. Levels of the inflammatory cytokines IL-8, TNF-α, and IL-17A in the sputum supernatant and in the blood were markedly lowered, while IL-10 levels were unchanged. The proportion of Foxp3+Tregs in the total CD4+T cell population in the peripheral blood was drastically higher than that before treatment. The level of IL-17A was negatively correlated with the proportion of Foxp3+Tregs in CD4+T cells. SFC can reduce the levels of inflammatory factors and improve symptoms of COPD. The levels of inflammatory factors are associated with the variation of Foxp3+Tregs in COPD. This study was registered with http://www.chictr.org (Chinese Clinical Trial Register) as follows: ChiCTR-TNC-10001270.
  Respiratory research 01/2011; 12:142. · 3.36 Impact Factor
• Article: [Prognostic analysis of N2 non-small cell lung cancer].

  Qian-li Ma, De-ruo Liu, Yong-qing Guo, Bin Shi, Zhi-yi Song, Yan-chu Tian
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the surgical therapeutic strategy and prognostic factors for non-small cell lung cancer (NSCLC) with mediastinal lymph node metastasis (N2). The survival rate of 117 patients with N2 NSCLC treated surgically from January 1999 to May 2003 were analyzed. There were 88 male cases and 29 female cases, aged from 29 to 79 years. The procedure of operation (lobectomy, pneumonectomy and palliative resection), histological classification (squamous cell carcinoma, adenocarcinoma, mixed carcinoma, and large cell carcinoma and others), T primary tumor status, and adjuvant therapy were analyzed to determine their impact on the 5-year survival rate. The median survival time was 22 months, and the over-all 3- and 5-year survival rate was 28.1% and 19.0%. Survival was higher in patients with lobectomy than with palliative resection, with T1 and T2 than with T4. The 5-year survival rate had no deference in age, sex and different histological classification. The 5-year survival rates of lobectomy and pneumonectomy (22.2% and 25.0% respectively) was higher than palliative resection (9.1%). Surgical procedures (especially lobectomy) is the best choice for N2 NSCLC patients with T1 or T2. But it can not prolong T4 patients' life significantly.
  Zhonghua wai ke za zhi [Chinese journal of surgery] 07/2009; 47(14):1058-60.